EVFM vs. SPRC, EVLO, BLPH, HSTO, CMRA, SBFM, SXTC, APVO, ADTX, and GRI
Should you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include SciSparc (SPRC), Evelo Biosciences (EVLO), Bellerophon Therapeutics (BLPH), Histogen (HSTO), Comera Life Sciences (CMRA), Sunshine Biopharma (SBFM), China SXT Pharmaceuticals (SXTC), Aptevo Therapeutics (APVO), Aditxt (ADTX), and GRI Bio (GRI). These companies are all part of the "pharmaceutical preparations" industry.
Evofem Biosciences (NASDAQ:EVFM) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.
0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 0.2% of Evofem Biosciences shares are held by company insiders. Comparatively, 1.5% of SciSparc shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Evofem Biosciences received 260 more outperform votes than SciSparc when rated by MarketBeat users. Likewise, 69.50% of users gave Evofem Biosciences an outperform vote while only 66.67% of users gave SciSparc an outperform vote.
Evofem Biosciences has a net margin of 290.81% compared to SciSparc's net margin of 0.00%. SciSparc's return on equity of 0.00% beat Evofem Biosciences' return on equity.
Evofem Biosciences has a beta of -1.04, indicating that its share price is 204% less volatile than the S&P 500. Comparatively, SciSparc has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.
In the previous week, SciSparc had 1 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for SciSparc and 1 mentions for Evofem Biosciences. SciSparc's average media sentiment score of 1.44 beat Evofem Biosciences' score of 0.00 indicating that SciSparc is being referred to more favorably in the news media.
Evofem Biosciences has higher revenue and earnings than SciSparc.
Summary
SciSparc beats Evofem Biosciences on 7 of the 13 factors compared between the two stocks.
Get Evofem Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evofem Biosciences Competitors List
Related Companies and Tools
